Metsera(MTSR.US)暴涨超60% 获辉瑞溢价收购

Core Viewpoint - Metsera, a startup focused on obesity drug development, saw its stock surge over 60% to a record high of $53.47 following Pfizer's agreement to acquire the company for approximately $4.9 billion, enhancing its research pipeline [1] Group 1: Acquisition Details - Pfizer will acquire Metsera for $47.50 per share in cash, with potential additional payments of up to $22.50 per share contingent on achieving three specific regulatory milestones [1] - The acquisition price represents a 43% premium over Metsera's closing price last Friday [1]